Basic Information
| LncRNA/CircRNA Name | ZEB2-AS1 |
| Synonyms | ZEB2-AS1, ZEB2-AS, ZEB2AS, ZEB2NAT |
| Region | GRCh38_2:144518097-144521477 |
| Ensemble | ENSG00000238057 |
| Refseq | NR_040248 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung cancer |
| ICD-0-3 | C34 |
| Methods | Western blot, in vitro knockdown etc. |
| Sample | lung cancer cell lines (H-125, A549, 95D, NCI-H292, H1975), lung cancer tissues |
| Expression Pattern | up-regulated |
| Function Description | ranscript level of ZEB2-AS1 in human lung cancer was markedly upregulated in vivo and in vitro. The knockdown of ZEB2-AS1 in A549 and NCI-H292 cells, and the overexpression of ZEB2-AS1 in H-125 and H1975 cells, altered colony formation and cell proliferative rate, as examined using colony formation and cell proliferation assays. Similarly, the overexpression of ZEB2-AS1 in H-125 and H1975 cells resulted in decreased expression of caspase-3, caspase-9, Bcl-2 and Bax. The results identified the effects of lncRNA ZEB2-AS1 on lung cancer progression through promoting its proliferation and inhibiting cell apoptosis, indicating that ZEB2-AS1 may serve as a novel prognostic factor for the diagnosis and treatment of human lung cancer in the clinic. |
| Pubmed ID | 29552161 |
| Year | 2018 |
| Title | Long non-coding RNA ZEB2-AS1 promotes proliferation and inhibits apoptosis in human lung cancer cells. |
External Links
| Links for ZEB2-AS1 | GenBank HGNC NONCODE |
| Links for lung cancer | OMIM COSMIC |